Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Catalyst Pharmaceuticals Stock Is Falling Today

By Brian Feroldi - Nov 13, 2019 at 11:20AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares sink after the company announces mixed third-quarter results and issues disappointing guidance.

What happened

In response to management announcing mixed third-quarter results and sharing tepid guidance, shares of Catalyst Pharmaceuticals ( CPRX -2.83% ), a commercial-stage biopharma focused on rare diseases, dropped 12% as of 11:03 a.m. EST on Wednesday.

So what

Here are some headline numbers from the quarter:

  • Product revenue from Firdapse -- the company's treatment for adults with Lambert-Eaton myasthenic syndrome (LEMS) -- was $30.9 million. That was behind the $34 million that Wall Street was expecting.
  • Net income was $13.6 million, or $0.13 per share. That was higher than the $0.11 consensus estimate in the analyst community.
  • The cash balance at quarter-end was $81.6 million.
Blue pills sitting on top of a pile of cash.

Image source: Getty Images.

Catalyst's CEO Patrick McEnany commented:

While the U.S. launch of Firdapse remains our primary focus, we have made significant progress on our other strategic priorities. These include our recent filing of a New Drug Submission (NDS) for Firdapse with Health Canada, for which we have been granted a Priority Review. In addition, we recently met with Japanese regulatory authorities about registration requirements to obtain approval of Firdapse for Japan. Our team has done an excellent job in executing our business plan this year, and we are on track to meet all of our goals and objectives for 2019 as we move into the new year.

Management also provided investors with revenue guidance for fiscal years 2019 and 2020.

For 2019, the company expects to generate about $100 million in total revenue. That's well below the $111 million that Wall Street was expecting. For 2020, management projects revenue to land between $135 million and $155 million. That's also short of the $166 million that analysts had modeled.

Given the weaker-than-expected revenue and guidance, it's no surprise to see the share price getting hit today.

Now what

There are positive and negative takeaways from this report.

The good news is that Catalyst is growing the top line and generating profits. That's rare given that Catalyst is still a small-cap pharmaceutical company. The balance sheet is in great shape, too.

The bad news is that management is doing a poor job of managing Wall Street's expectations. Part of the disappointing guidance could be a result of rising competition, which isn't great news for investors.

My view is that Catalyst is an intriguing business, but it's still very risky. My plan is to root for this company's success from the safety of the sidelines.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Catalyst Pharmaceuticals, Inc. Stock Quote
Catalyst Pharmaceuticals, Inc.
CPRX
$6.86 (-2.83%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
624%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/05/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.